PIK3CA and neoplasm: Targeting the PI3-kinase (PI3K) pathway in triple-negative breast cancer is a promising therapeutic strategy because this pathway is dysregulated in approximately 25% of TNBC patients, driving tumor growth, survival, and resistance to therapy [62].